Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- Poxel has signed a deal with Sumitomo Dainippon Pharma to jointly develop its Type 2 Diabetes product Imeglimin
- Berlin’s largest biotech Glycotope has hammered out a deal with Daiichi Sankyo for its antibody-drug conjugates
Images via kungverylucky, Kobby Dagan, Parkol / shutterstock.com